Figure 1 | British Journal of Cancer

Figure 1

From: Feasibility of proposed single-nucleotide polymorphisms as predictive markers for targeted regimens in metastatic colorectal cancer

Figure 1

Progression-free survival (PFS) and overall survival (OS) in all patients treated with cetuximab regimens ( A and B ) and in those who had received three or more chemotherapy lines ( C and D ), between patients carrying wild-type alleles ( GG ) of LIFR rs3729740 and those carrying mutant allele(s) ( GA/AA). Progression-free survival and OS in all patients treated with bevacizumab regimens, between patients carrying minor alleles (TT) of ANXA11 rs1049550 and those carrying ancestral allele(s) (CC and CT; E and F). P-values using Kaplan–Meier method by a log-rank test are displayed over the bars. Bold font, P<0.05.

Back to article page